Crain’s Cleveland Business: The U.S. Is Losing Its Biotech Edge

06/26/2025

Biotech is one of America’s most critical innovation sectors, but it is facing serious headwinds. Since COVID-19, the industry has been hammered by falling investor confidence, sluggish IPO markets, and rising international competition. 

If we do not act to strengthen the United States’ biotech sector, we risk surrendering our global leadership to countries like China, which are aggressively scaling biotech industries without the same standards for safety and data accuracy.

CLICK HERE to read Dr. Gabi Hanna’s full opinion column in Crain’s Cleveland Business.

READ MORE

06/06/2025

Crain’s Cleveland Business: Cleveland biotech company secures $2.7M in NIH funding

Lamassu Biotech, a company with its “second headquarters” in Cleveland, has received a $2.7 million grant from the National Institutes of Health (NIH). The funds will help support the development of a novel treatment protocol for acute pancreatitis in canines....

READ THE ARTICLE
06/04/2025

Cleveland Business Journal: Lamassu Biotech’s dog treatment could lead to human pancreatitis breakthrough, backed by NIH funds

Lamassu Biotech, the North Carolina-based biopharmaceutical company that opened a Cleveland office last year, has received a $2.7 million grant from the National Institutes of Health to help develop its therapy for dogs with acute pancreatitis. The therapeutic, called RABI-767, also could...

READ THE ARTICLE
04/08/2025

The Washington Times: Biotech should take a page from Elon Musk’s playbookThe Washington Post:

Innovation has always been the foundation of progress, but how we innovate matters as much as the results we achieve. Recent breakthroughs in aerospace and artificial intelligence prove that massive budgets don’t drive innovation, but efficiency, speed and a relentless...

READ THE ARTICLE